Use of the BRAF inhibitor vemurafenib in patients with advanced metastatic papillary thyroid cancer (PTC) with the V600E BRAF mutation resulted in either a partial response or stable disease in those patients, according to data reported at the American Thyroid Association Annual Meeting.
The mutation is found in approximately 40 percent of primary PTC tumors and up to 80 percent of recurrent tumors, the study's first author, Ramona Dadu, MD, an endocrinology fellow in the Department of Endocrinology, Neoplasia, and Hormonal Disorders at the University of Texas MD Anderson Cancer Center, explained via email. “Patients have a poor overall prognosis, and there is an unmet need for therapeutic agents.”
In the study of 12 patients with advanced metastatic PTC with the V600E BRAF mutation treated with vemurafenib, three had a reduction of tumor size of at least 30 percent, and the other nine patients had stable disease after treatment (five having had a 10 to 29 percent reduction in tumor size).
These results are “very encouraging,” Dadu noted—“and will likely represent the basis for a Phase III trial.”